Identifying protective dengue vaccines: Guide to mastering an empirical process

Vaccine

Volumn 31, Issue 41, 2013, Pages 4501-4507

  Halstead, Scott B ^a  

^a Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

Antibodies; Dengue fever; Dengue hemorrhagic fever; Dengue virus; T cells; Vaccine; Vaccine challenge; Vaccine protection

Indexed keywords

DENGUE VACCINE; NEUTRALIZING ANTIBODY; ANTIBODY; VACCINE;

ANTIBODY RESPONSE; BLOOD VESSEL PERMEABILITY; DENGUE; DENGUE VIRUS 2; DRUG EFFICACY; DRUG SCREENING; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTECTION; REVIEW; VIRUS IMMUNITY; ANIMAL; CLINICAL TRIAL (TOPIC); HUMAN; IMMUNOLOGY; MEDICAL RESEARCH; PRECLINICAL STUDY; PROCEDURES; TREATMENT OUTCOME; VACCINATION; DENGUE VIRUS; METHODOLOGY; T LYMPHOCYTE; VACCINE CHALLENGE; VACCINE PROTECTION;

ANIMALS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DENGUE; DENGUE VACCINES; DRUG EVALUATION, PRECLINICAL; HUMANS; TREATMENT OUTCOME; VACCINATION;

ANTIBODIES; DENGUE FEVER; DENGUE HEMORRHAGIC FEVER; DENGUE VIRUS; T CELLS; VACCINE; VACCINE CHALLENGE; VACCINE PROTECTION;

EID: 84883597357     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.06.079     Document Type: Review

References (79)

1. Thomas S.J., Endy T.P. Vaccines for the prevention of dengue: development update. Hum Vaccin 2011, 7(6):674-684.
2. Durbin A.P., Whitehead S.S. Dengue vaccine candidates in development. Curr Top Microbiol Immunol 2010, 338:129-143.
3. Durbin A.P., Whitehead S.S. Next-generation dengue vaccines: novel strategies currently under development. Viruses 2011, 3(10):1800-1814.
4. Guy B., Barrere B., Malinowski C., Saville M., Teyssou R., Lang J. From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011, 29(42):7229-7241.
5. Schmitz J., Roehrig J., Barrett A., Hombach J. Next generation dengue vaccines: a review of candidates in preclinical development. Vaccine 2011, 29(42):7276-7284.
6. Coller B.A., Clements D.E., Bett A.J., Sagar S.L., Ter Meulen J.H. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine 2011, 29(42):7267-7275.
7. Osorio J.E., Huang C.Y., Kinney R.M., Stinchcomb D.T. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine 2011, 29(42):7251-7260.
8. Durbin A.P., Kirkpatrick B.D., Pierce K.K., Elwood D., Larsson C.J., Lindow J.C., et al. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J Infect Dis 2013, 207(6):957-965.
9. Simasathien S., Thomas S.J., Watanaveeradej V., Nisalak A., Barberousse C., Innis B.L., et al. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am J Trop Med Hyg 2008, 78(3):426-433.
10. Sabchareon A., Wallace D., Sirivichayakul C., Limkittikul K., Chanthavanich P., Suvannadabba S., et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012, 380(9853):1559-1567.
11. Halstead S.B. Dengue vaccine development: a 75% solution?. Lancet 2012, 380(9853):1535-1536.
12. Yauch L.E., Zellweger R.M., Kotturi M.F., Qutubuddin A., Sidney J., Peters B., et al. A protective role for dengue virus-specific CD8+ T cells. J Immunol 2009, 182(8):4865-4873.
13. Cleland J.B., Bradley B., Macdonald W. Further Experiments in the Etiology of Dengue Fever. J Hyg (Lond) 1919, 18(3):217-254.
14. Simmons J.S. St John JH, Reynolds FHK. Experimental studies of dengue. Philipp J Sci 1931, 44:1-252.
15. Sabin A.B., Schlesinger R.W. Production of immunity to dengue with virus modified by propagation in mice. Science 1945, 101:640-642.
16. Sabin A.B. Research on dengue during World War II. Am J Trop Med Hyg 1952, 1:30-50.
17. Johnson A.J., Roehrig J.T. New mouse model for dengue virus vaccine testing. J Virol 1999, 73(1):783-786.
18. Huang C.Y., Butrapet S., Tsuchiya K.R., Bhamarapravati N., Gubler D.J., Kinney R.M. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J Virol 2003, 77(21):11436-11447.
19. Simmons J.S., St John J.H., Reynolds F.H.K. Experimental Studies of Dengue. Philip J Sci 1931, 44(1-2):1-252.
20. Roehrig J.T., Bolin R.A., Kelly R.G. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 1998, 246(2):317-328.
21. Whitehead R.H., Chaicumpa V., Olson L.C., Russell P.K. Sequential dengue virus infections in the white-handed gibbon (hylobates lar). Am J Trop Med Hyg 1970, 19(1):94-102.
22. Halstead S.B., Casals J., Shotwell H., Palumbo N. Studies on the immunization of monkeys against dengue. 1. protection derived from single and sequential virus infections. Am J Trop Med Hyg 1973, 22(3):365-374.
23. Putnak R.J., Coller B.A., Voss G., Vaughn D.W., Clements D., Peters I., et al. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 2005, 23(35):4442-4452.
24. Durbin A.P., Whitehead S.S., Shaffer D., Elwood D., Wanionek K., Thumar B., et al. A Single Dose of the DENV-1 Candidate Vaccine rDEN1Delta30 Is Strongly Immunogenic and Induces Resistance to a Second Dose in a Randomized Trial. PLoS Negl Trop Dis 2011, 5(8):e1267.
25. Amanna I.J., Hammarlund E., Lewis M.W., Slifka M.K. Impact of infection or vaccination on pre-existing serological memory. Hum Immunol 2012, 73(11):1082-1086.
26. de Alwis R., Smith S.A., Olivarez N.P., Messer W.B., Huynh J.P., Wahala W.M., et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci USA 2012, 109(19):7439-7444.
27. Teoh E.P., Kukkaro P., Teo E.W., Lim A.P., Tan T.T., Yip A., et al. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med 2012, 4(139):139ra83.
28. Bellanti J.A., Bourke A.T.C., Buescher E.L., Cadigan F.C., Cole G.A., El Batawi Y., et al. Report of dengue vaccine trial in the Caribbean, 1963: a collaborative study. Bull WHO 1966, 35:93.
29. Watts D.M., Porter K.R., Putvatana P., Vasquez B., Calampa C., Hayes C.G., et al. Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever. Lancet 1999, 354(9188):1431-1434. [see comments].
30. Kochel T.J., Watts D.M., Halstead S.B., Hayes C.G., Espinosa A., Felices V., Caceda R., Bautista T., Montoya Y., Douglas S., Russell K.L. Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever. Lancet 2002, 360:310-312.
31. Kochel T.J., Watts D.M., Gozalo A.S., Ewing D.F., Porter K.H., Russell K.L. Cross-serotype neutralization of dengue virus in Aotus nancymae monkeys. J Infect Dis 2005, 191:1000-1004.
32. Guzman M.G., Kouri G., Valdes L., Bravo J., Vazquez S., Halstead S.B. Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev Panam Salud Publica 2002, 11(4):223-227.
33. Guzman M.G., Alvarez M., Rodriguez-Roche R., Bernardo L.M., T.Vazquez S., Morier L., et al. Neutralizing antibodies after infection with dengue 1 virus. Emerg Infect Dis 2007, 13:282-286.
34. Kyle J.L., Balsitis S.J., Zhang L., Beatty P.R., Harris E. Antibodies play a greater role than immune cells in heterologous protection against secondary dengue virus infection in a mouse model. Virology 2008, 380(2):296-303.
35. Williams K.L., Zompi S., Beatty P.R., Harris E. A mouse model for studying dengue virus pathogenesis and immune response. Ann NY Acad Sci 2009, 1171(Suppl 1):E12-E23.
36. Zompi S., Santich B.H., Beatty P.R., Harris E. Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells. J Immunol 2012, 188(1):404-416.
37. Weiskopf D., Yauch L.E., Angelo M.A., John D.V., Greenbaum J.A., Sidney J., et al. Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design. J Immunol 2011, 187(8):4268-4279.
38. Weiskopf D., Angelo M.A., de Azeredo E.L., Sidney J., Greenbaum J.A., Fernando A.N., et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci USA 2013.
39. Kliks S.C., Nisalak A., Brandt W.E., Wahl L., Burke D.S. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 1989, 40(4):444-451.
40. Moi M.L., Takasaki T., Kurane I. Efficacy of tetravalent dengue vaccine in Thai schoolchildren. Lancet 2013, 381(9872):1094.
41. Halstead S.B. Observations related to pathogenesis of dengue hemorrhagic fever VI. hypotheses and discussion. Yale J Biol Med 1970, 42:350-362.
42. Fischer D.B., Halstead S.B. Observations related to pathogenesis of dengue hemorrhagic fever. V. Examination of age specific sequential infection rates using a mathematical model. Yale J Biol Med 1970, 42:329-349.
43. Gibbons R.V., Kalanarooj S., Jarman R.G., Nisalak A., Vaughn D.W., Endy T.P., et al. Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Am J Trop Med Hyg 2007, 77(5):910-913.
44. Russell P.K., Udomsakdi S., Halstead S.B. Antibody response in dengue and dengue hemorrhagic fever. Jpn J Med Sci Biol 1967, 20:103-108.
45. Zompi S., Montoya M., Pohl M.O., Balmaseda A., Harris E. Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans. PLoS Negl Trop Dis 2012, 6(3):e1568.
46. Guy B., Barban V., Mantel N., Aguirre M., Gulia S., Pontvianne J., et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg 2009, 80(2):302-311.
47. Kitchener S., Nissen M., Nasveld P., Forrat R., Yoksan S., Lang J., et al. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 2006, 24(9):1238-1241.
48. Sun W., Cunningham D., Wasserman S.S., Perry J., Putnak J.R., Eckels K.H., et al. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults. Hum Vaccin 2009, 5(1):33-40.
49. Anderson K.B., Gibbons R.V., Edelman R., Eckels K.H., Putnak R.J., Innis B.L., et al. Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate. J Infect Dis 2011, 204(3):442-450.
50. Osorio J.E., Brewoo J.N., Silengo S.J., Arguello J., Moldovan I.R., Tary-Lehmann M., et al. Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques. Am J Trop Med Hyg 2011, 84(6):978-987.
51. Guirakhoo F., Pugachev K.V. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 2002, 298:146-159.
52. Guirakhoo F., Pugachev K., Zhang Z., Myers G., Levenbook I., Draper K., et al. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 2004, 78(9):4761-4775.
53. Morrison D., Legg T.J., Billings C.W., Forrat R., Yoksan S., Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 2010, 201(3):370-377.
54. Sutter R.W., Kew O.M., Cochi S.L. Polio Vaccine-Live. Vaccines 2008, 385-431. Saunders Elsevier, Philadelphia. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
55. Guirakhoo F., Weltzin R., Chambers T.J., Zhang Z., Soike K., Ratterree M., et al. Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus Is Immunogenic and Protective in Nonhuman Primates. J Virol 2000, 74(12):5477-5485.
56. Guirakhoo F., Kitchener S., Morrison D., Forat R., McCarthy K., Nichols R., et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2006, 2:60-67.
57. Endy T.P., Nisalak A., Chunsuttiwat S., Vaughn D.W., Green S., Ennis F.A., et al. The relationship of pre-existing dengue virus neutralizing antibody levels to viremia and disease severity in a prospective cohort study of dengue in Thailand. J Infect Dis 2004, 189:990-1000.
58. Durbin A.P., Whitehead S.S. The dengue human challenge model: has the time come to accept this challenge?. J Infect Dis 2013, 207(5):697-699.
59. Sun W., Eckels K.H., Putnak J.R., Lyons A.G., Thomas S.J., Vaughn D.W., et al. Experimental Dengue Virus Challenge of Human Subjects Previously Vaccinated With Live Attenuated Tetravalent Dengue Vaccines. J Infect Dis 2013, 207(5):700-708.
60. Bhamarapravati N., Yoksan S. Live attenuated tetravalent dengue vaccine. Dengue and dengue hemorrhagic fever 1997, 367-377. CAB International, New York. D.J. Gubler, G. Kuno (Eds.).
61. Sanchez V., Gimenez S., Tomlinson B., Chan P.K., Thomas G.N., Forrat R., et al. Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3). Vaccine 2006, 24(23):4914-4926.
62. Sun W., Edelman R., Kanesa-Thasan N., Eckels K.H., Putnak J.R., King A.D., et al. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 2003, 69(6 Suppl):24-31.
63. Sabchareon A., Lang J., Chanthavanich P., Yoksan S., Forrat R., Attanath P., et al. Safety and immunogenicity of two tetravalent live attenuated dengue vaccines in 5-12 year old Thai children. Pediatr Infect Dis J 2004, 23:99-109.
64. Querec T.D., Akondy R.S., Lee E.K., Cao W., Nakaya H.I., Teuwen D., et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009, 10(1):116-125.
65. Ahmed R., Akondy R.S. Insights into human CD8(+) T-cell memory using the yellow fever and smallpox vaccines. Immunol Cell Biol 2011, 89(3):340-345.
66. Yauch L.E., Prestwood T.R., May M.M., Morar M.M., Zellweger R.M., Peters B., et al. CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination. J Immunol 2010, 185(9):5405-5416.
67. Tam D.T., Ngoc T.V., Tien N.T., Kieu N.T., Thuy T.T., Thanh L.T., et al. Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial. Clin Infect Dis 2012, 55(9):1216-1224.
68. Halstead S.B. Dengue vascular permeability syndrome: what no T cells?. Clin Infect Dis 2013, 56(6):900-901.
69. Russell P.K., Chiewsilp D., Brandt W.E. Immunoprecipitation analysis of soluble complement-fixing antigens of dengue viruses. J Immunol 1970, 105:838-845.
70. Avirutnan P., Punyadee N., Noisakran S., Komoltri C., Thiemmeca S., Auethavornanan K., et al. Vascular leakage in severe dengue virus infections: A potential role for the nonstructural viral protein NS1 and complement. J Infect Dis 2006, 193:1078-1088.
71. Memoranda Pathogenic mechanisms in dengue hemorrhagic fever. Report of an international collaborative study. Bull WHO 1973, 48:117-132.
72. Lin S.W., Chuang Y.C., Lin Y.S., Lei H.Y., Liu H.S., Yeh T.M. Dengue virus nonstructural protein NS1 binds to prothrombin/thrombin and inhibits prothrombin activation. J Infect 2012, 64(3):325-334.
73. Wills B., Tran V.N., Nguyen T.H., Truong T.T., Tran T.N., Nguyen M.D., et al. Hemostatic changes in Vietnamese children with mild dengue correlate with the severity of vascular leakage rather than bleeding. Am J Trop Med Hyg 2009, 81(4):638-644.
74. Schlesinger J.J., Brandriss M.W., Walsh E.E. Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. J Gen Virol 1987, 68:853-857.
75. Schlesinger J.J., Foltzer M., Chapman S. The Fc portion of antibody to yellow fever virus-ns1 is a determinant of protection against YF encephalitis in mice. Virology 1993, 192:132-141.
76. Schlesinger J.J., Brandriss M.W., Walsh E.E. Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48. J Immunol 1985, 135(4):2805-2809.
77. Schlesinger J.J., Brandriss M.W., Cropp C.B., Monath T.P. Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. J Virol 1986, 60(3):1153-1155.
78. Henchal E.A., Henchal L.S., Schlesinger J.J. Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus. J Gen Virol 1988, 69:2101-2107.
79. Falgout B., Bray M., Schlesinger J.J., Lai C.J. Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis. J Virol 1990, 64(9):4356-4363.